| Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... Cancer discovery 3 (12), 1416-1429, 2013 | 471* | 2013 |
| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ... Scientific reports 4 (1), 1-10, 2014 | 358 | 2014 |
| Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin MM Bespalov, YA Sidorova, S Tumova, A Ahonen-Bishopp, ... Journal of Cell Biology 192 (1), 153-169, 2011 | 254 | 2011 |
| Methods for high-throughput drug combination screening and synergy scoring L He, E Kulesskiy, J Saarela, L Turunen, K Wennerberg, T Aittokallio, ... Cancer systems biology: methods and protocols, 351-398, 2018 | 211 | 2018 |
| PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells O Kauko, CM O’Connor, E Kulesskiy, J Sangodkar, A Aakula, S Izadmehr, ... Science translational medicine 10 (450), eaaq1093, 2018 | 156 | 2018 |
| N-syndecan deficiency impairs neural migration in brain A Hienola, S Tumova, E Kulesskiy, H Rauvala The Journal of cell biology 174 (4), 569-580, 2006 | 144 | 2006 |
| Expression of the recombinant antibacterial peptide sarcotoxin IA in Escherichia coli cells VS Skosyrev, EA Kulesskiy, AV Yakhnin, YV Temirov, LM Vinokurov Protein expression and purification 28 (2), 350-356, 2003 | 101 | 2003 |
| Antifungal application of nonantifungal drugs M Stylianou, E Kulesskiy, JP Lopes, M Granlund, K Wennerberg, ... Antimicrobial agents and chemotherapy 58 (2), 1055-1062, 2014 | 83 | 2014 |
| Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg, S Potdar, A Kyttälä, ... BMC cancer 19, 1-14, 2019 | 76 | 2019 |
| Identification and tracking of antiviral drug combinations A Ianevski, R Yao, S Biza, E Zusinaite, A Männik, G Kivi, A Planken, ... Viruses 12 (10), 1178, 2020 | 70 | 2020 |
| Phosphoproteomics to characterize host response during influenza A virus infection of human macrophages S Söderholm, DE Kainov, T Öhman, OV Denisova, B Schepens, ... Molecular & cellular proteomics 15 (10), 3203-3219, 2016 | 70 | 2016 |
| HB-GAM (pleiotrophin) reverses inhibition of neural regeneration by the CNS extracellular matrix M Paveliev, KK Fenrich, M Kislin, J Kuja-Panula, E Kulesskiy, M Varjosalo, ... Scientific reports 6 (1), 33916, 2016 | 64 | 2016 |
| Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1 O Kauko, SY Imanishi, E Kulesskiy, L Yetukuri, TD Laajala, M Sharma, ... Journal of Biological Chemistry 295 (13), 4194-4211, 2020 | 63 | 2020 |
| Drug-sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy T Lepikhova, PR Karhemo, R Louhimo, B Yadav, A Murumägi, ... Molecular cancer therapeutics 17 (9), 2060-2071, 2018 | 51 | 2018 |
| Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins D Bulanova, A Ianevski, A Bugai, Y Akimov, S Kuivanen, H Paavilainen, ... Viruses 9 (10), 271, 2017 | 48 | 2017 |
| Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma IB Quintero, AM Herrala, CL Araujo, AE Pulkka, S Hautaniemi, K Ovaska, ... PloS one 8 (9), e73072, 2013 | 37 | 2013 |
| High NRF2 levels correlate with poor prognosis in colorectal cancer patients and with sensitivity to the kinase inhibitor AT9283 in vitro L Torrente, G Maan, A Oumkaltoum Rezig, J Quinn, A Jackson, A Grilli, ... Biomolecules 10 (10), 1365, 2020 | 35 | 2020 |
| Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells UM Haltia, N Andersson, B Yadav, A Färkkilä, E Kulesskiy, M Kankainen, ... Gynecologic oncology 144 (3), 621-630, 2017 | 35 | 2017 |
| Precision cancer medicine in the acoustic dispensing era: ex vivo primary cell drug sensitivity testing E Kulesskiy, J Saarela, L Turunen, K Wennerberg Journal of laboratory automation 21 (1), 27-36, 2016 | 32 | 2016 |
| Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment E Skaga, E Kulesskiy, M Brynjulvsen, CJ Sandberg, S Potdar, ... Clinical and translational medicine 8, 1-15, 2019 | 27 | 2019 |
Tero AittokallioUniversity of Helsinki, University of Turku, University of OsloVerified email at utu.fi